Product
ADSTILADRIN
Name
ADSTILADRIN
INN Name
nadofaragene firadenovec-vncg
FDA Approved
Yes
2 clinical trials
1 organization
1 indication
1 document
Indication
Bladder CancerClinical trial
A Phase III, Open Label Study to Evaluate the Safety and Efficacy of INSTILADRIN® (rAd-IFN)/Syn3) Administered Intravesically to Patients With High Grade, BCG Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC)Status: Completed, Estimated PCD: 2019-05-24
Clinical trial
ADSTILADRIN Early Utilization and Outcomes in the Real World Setting in the United StatesStatus: Recruiting, Estimated PCD: 2025-12-31
Document
DailyMed Label: ADSTILADRINOrganization
Ferring Pharmaceuticals Inc.